Rate My Professor Paul Welsh

Professor Paul Welsh is Professor of Molecular Epidemiology in the School of Cardiovascular & Metabolic Health at the University of Glasgow. He holds a BSc (Hons) in Immunology and a PhD from the University of Glasgow, where his 2008 doctoral thesis examined inflammatory markers as novel predictors of cardiovascular disease under Professor Gordon Lowe. Welsh also completed an MSc in Epidemiology with distinction at the London School of Hygiene and Tropical Medicine in 2014, earning the 150th Anniversary prize. Post-PhD, he worked with Professor Naveed Sattar, supported by a British Heart Foundation Advanced Training Fellowship in 2010 and an Intermediate Basic Scientist Fellowship in 2013. He was promoted to Readership in 2019 and appointed to his Chair in 2023. As Director of the Glasgow Biomarker Research Unit (GlasBRU), Welsh leads a laboratory performing routine and specialized biomarker assays on blood, urine, and saliva for epidemiological studies and clinical trials.

His research focuses on epidemiological analyses of risk factors for cardiovascular disease, diabetes, heart failure, and related conditions using circulating biomarkers including NT-proBNP, high-sensitivity troponin, lipoprotein(a), inflammatory markers, and metabolomic profiles to predict clinical outcomes such as mortality, stroke, and microvascular events. Welsh contributes to major cohorts like UK Biobank, Generation Scotland, Lothian Birth Cohort, and MIDSPAN Family Study, and trials such as DAPA-HF, DiRECT, ADVANCE, TARTAN-HF, EMPRESS-MI, and PRIZE. Key publications include "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials" (2010), "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial" (2018), "Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial" (2019), and "Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes" (2019). These highly cited works have enhanced biomarker applications in risk prediction and cardiometabolic patient care.